Effective GLP-1 Drug Development Online Summit
We are delighted to invite you to the Effective GLP-1 Drug Development Summit, a focused session bringing together leading experts to discuss innovative strategies and analytical solutions for GLP-1 drug development. This event will cover all aspects of drug development.
HIGHLIGHTS
Advancing GLP-1 Therapeutics—A Scientific Imperative to Address Early Development and Manufacturing Challenges
The therapeutic renaissance of GLP-1 receptor agonists has catalyzed a paradigm shift in the treatment of metabolic disorders. Originally developed for glycemic control in type 2 diabetes, GLP-1 analogs now demonstrate robust efficacy in obesity, cardiovascular risk reduction, and in other treatments. With the next frontier of these blockbuster therapeutics well on its way to approval, the GLP-1 field is only going to grow, with novel combinations, indications, and formulations being explored.
Scientific Complexity in Early Development
The pharmacological success of GLP-1 is underpinned by their pleiotropic effects on insulin secretion, appetite regulation, and gastric emptying. Yet, translating these mechanisms into next-generation therapies—such as dual and triple incretin agonists—requires a nuanced understanding of receptor dynamics, biased agonism, and tissue-specific signaling. As peptides become more popular in the development of new therapeutics, it is increasingly important to quickly optimize the synthetic and cleavage processes by isolating and identifying both the target peptide and its related impurities.
Manufacturing: A Peptide-Specific Bottleneck
From a bioprocessing perspective, GLP-1 analogs present unique challenges due to their peptide nature:
- Peptide Stability: GLP-1 analogs are prone to degradation due to their sensitivity to temperate, pH and enzymatic activity.
- Purity requirement: High purity is essential for therapeutics peptides, as impurities can affect efficacy and safety.
- Complex synthesis: Involves solid-phase peptide synthesis, which can lead to incomplete couplings, deletion sequences and side reaction, requiring optimization.
- Scalability: Transition from small-scale synthesis to large scale manufacturing while maintaining consistency and quality is challenging
AGENDA
- Accelerating Method Development and QC with LC-UV-MS for GLP-1 Agonists
- Steve Calciano
- Characterisation of GLP-1 Peptides and Impurities using HRMS and Ion Mobility
- Jon Fox
- Light Scattering solutions to analyse oligomeric state and aggregation in GLP-1 formulations
- Sophia Kenrick
- Bio-Analytical Quantification of GLP-1 Peptides: A Case Study on Semaglutide
- Henry Foddy
- Panel Discussion with All Speakers
Why Attend?
Gain insights into cutting-edge analytical techniques, practical case studies, and collaborative discussions to advance GLP-1
Presenter: Antonia Wierzbicki (Principal MS Market Dev Manager, EMEA, Waters Corporation)
Antonia Wierzbicki is a MS market development manager at Waters working in EMEA. Antonia has BSc in Pharmaceutical Science and a MSc in Cancer Pharmacology.
Following several years working as an analytical chemist in drug development roles within both academic labs and contract research organizations, Antonia has more recently spent time working with analytical chemists to provide solutions using cutting edge technologies to meet their needs and requirements, with a specific interest in ultra-sensitive quantitation of small molecules.
Antonia is based in Cambridge UK and keen to connectwith like-minded scientists in the field.
Presenter: Sophia Kenrick, Ph.D. (Director of Analytical Sciences, Waters | Wyatt Technology)
Sophia received her Ph.D. in Chemical Engineering from the University of California, Santa Barbara, USA, where she utilized a variety of biophysical techniques, including surface plasmon resonance and quantitative flow cytometry, for characterizing combinatorial protein-binding ligands.
Sophia joined Wyatt in 2010 and has provided support to the Sales and Marketing teams and R&D product development efforts. She supports multiple applications for Wyatt instrumentation, especially in the field of molecular recognition and biomolecular interactions.
Presenter: Henry Foddy (Associate Scientist, Waters Corporation)
Henry is a Scientist in the Routine Mass Detection Team at Waters, working on applications to support Waters’ single quadrupole portfolio that span a variety of market segments. He has almost 3 years of experience with Waters, working previously in a food and environmental role support regulatory testing of Pesticides, PFAS, and Pyrrolizidine Alkaloids. Prior to joining Waters, Henry obtained an MSc in Neuroscience from King’s College London.
Presenter: Steven Calciano (Senior Product Manager, Waters Corporation)
Steven Calciano joined Waters Corporation in 2015 and is responsible bringing innovative large molecule chromatography and mass spectrometry sample preparationsolutions to market. Prior to his current role, Steven supported analytical standards andreagents products across pharmaceutical, environmental, chemical and food industries,gaining an understanding of a variety of complex analytical workflows. He strives to bringenabling technology to LC-MS users which simplify complex sample preparation methods.
Presenter: Jonathan Fox (Principal Applications Chemist, Waters Corporation)
Jonathan Fox is a Consulting Scientist within the Process Analytics Applications team at Waters, based in Wilmslow, UK. With extensive expertise in analytical science, Jonathan plays a pivotal role in advancing solutions that enable customers to achieve greater efficiency and precision in their workflows particularly for complex new modalities.
In his current role, Jonathan collaborates closely with cross-functional teams to develop and implement innovative analytical strategies for biological therapeutics. His work focuses on integrating cutting-edge instrumentation and software to support robust, data-driven decision-making in regulated environments.
Jonathan is a trusted technical advisor, and a key contributor to developing and demonstrating advanced analytical workflows. His deep understanding of characterising and identifying complex molecules such as oligonucleotides, peptides and therapeutic proteins; using advanced analytical instrumentation; and commitment to scientific excellence make him a valuable resource and partner for complex analytical workflows.
